| Phase 4 |
| NCT06409702 |
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease… |
Newly Diagnosed |
Recruiting |
| NCT07270835 |
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma |
Hemophagocytic Lymphohistiocytosis |
Recruiting |
| NCT06504030 |
Modified DEP Regimens for the Treatment of Hemophagocytic Lymphohistiocytosis |
Hemophagocytic Lymphohistiocytoses |
Not Yet Recruiting |
| NCT07709884 |
A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly… |
Newly Diagnosed Multiple Myeloma |
Not Yet Recruiting |
| Phase 3 |
| NCT06381817 |
Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients |
Acute T Cell Lymphoblastic Leukemia |
Recruiting |
| NCT07463651 |
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib |
Acute Myeloid Leukemia (AML) |
Recruiting |
| NCT05669079 |
Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT |
Poor Graft Function |
Not Yet Recruiting |
| NCT05907499 |
Decitabine for Poor Graft Function Post Allo-HSCT |
Poor Graft Function |
Not Yet Recruiting |
| NCT06673459 |
BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients |
T-Cell Lymphocytic Leukemia |
Not Yet Recruiting |
| NCT07486479 |
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and… |
Acute Myeloid Leukemia (AML) |
Not Yet Recruiting |
| NCT07635511 |
Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies |
Hematological Malignancies |
Not Yet Recruiting |
| Phase 2/3 |
| NCT05404906 |
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission |
Acute Myeloid Leukemia (AML) in Remission |
Recruiting |
| NCT05805098 |
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML |
Acute Myeloid Leukemia |
Recruiting |
| NCT05939180 |
VA vs DA for Newly Diagnosed Hig-risk AML |
Acute Myeloid Leukemia |
Recruiting |
| NCT07583888 |
VABu Conditioning in Elderly AML HSCT |
Allogeneic Hematopoietic Stem Cell Transplantation Recipient |
Recruiting |
| NCT05568147 |
Aspirin for Prophylaxis of TTP |
Thrombotic Thrombocytopenic Purpura |
Not Yet Recruiting |
| NCT06544109 |
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia… |
Acute Promyelocytic Leukemia |
Enrolling by Invitation |
| NCT06951971 |
Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic… |
Hemophagocytic Lymphohistiocytosis (HLH) |
Not Yet Recruiting |
| NCT07279610 |
N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy |
Thrombotic Microangiopathy |
Active, Not Recruiting |
| Phase 2 |
| NCT05521204 |
Olverembatinib for FGFR1-rearranged Neoplasms |
Myeloproliferative Neoplasm |
Recruiting |
| NCT06394011 |
Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML… |
Intermediate Risk Acute Myeloid Leukemia |
Recruiting |
| NCT06393985 |
Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With… |
B-cell Acute Lymphoblastic Leukemia |
Recruiting |
| NCT06626737 |
Dapagliflozin in Allo-HCT for aGVHD |
Graft-versus-host Disease (GVHD) |
Recruiting |
| NCT07007949 |
a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia |
Acute Myeloid Leukemia |
Recruiting |
| NCT06682130 |
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL |
Diffuse Large B-cell Lymphoma(DLBCL) |
Recruiting |